# Phase 3 Fallopian Tube cancer trials recruiting: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials in phase 3 for Fallopian Tube cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Fallopian Tube cancer trials: 22 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/fallopian-tube-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926048) |
| October 5, 2026 | NCT07859215 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line... | Genmab | Phase 3 | Not yet recruiting | Ovarian Cancer | 602 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859215) |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |
| September 10, 2026 | NCT07811271 | Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal... | BeOne Medicines | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811271) |
| August 28, 2026 | NCT07791732 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent... | Daiichi Sankyo | Phase 3 | Not yet recruiting | Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791732) |
| August 20, 2026 | NCT07776691 | A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer | 802 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776691) |
| August 3, 2026 | NCT07743164 | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 646 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743164) |
| May 22, 2026 | NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant... | Genmab | Phase 3 | Recruiting | Platinum-resistant Ovarian Cancer | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604766) |
| April 22, 2026 | NCT07545460 | A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545460) |
| October 9, 2025 | NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C)... | Eli Lilly and Company | Phase 3 | Recruiting | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis | 1,630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213804) |
| May 29, 2025 | NCT06994195 | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06994195) |
| April 7, 2025 | NCT06915025 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly... | Imunon | Phase 3 | Recruiting | Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06915025) |
| February 13, 2025 | NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06824467) |
| December 30, 2024 | NCT06751485 | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Not yet recruiting | Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751485) |
| February 21, 2023 | NCT05737303 | Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer | Women's Hospital School Of Medicine Zhejiang University | Phase 3 | Recruiting | Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III... | 538 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05737303) |
| December 21, 2022 | NCT05659381 | Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | GOG Foundation | Phase 3 | Recruiting | Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05659381) |
| March 16, 2022 | NCT05281471 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in... | Genelux Corporation | Phase 3 | Recruiting | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal... | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05281471) |
| August 17, 2021 | NCT05009082 | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | AGO Study Group | Phase 3 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 970 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05009082) |
| October 5, 2020 | NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube... | M.D. Anderson Cancer Center | Phase 3 | Recruiting | Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube... | 580 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04575935) |
| August 17, 2020 | NCT04515602 | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | Shanghai Gynecologic Oncology Group | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04515602) |
| October 2, 2019 | NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Swiss GO Trial Group | Phase 3 | Recruiting | Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma... | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04111978) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 3 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Imunon | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Swiss GO Trial Group | 1 |
| Women's Hospital School Of Medicine Zhejiang University | 1 |
| Shanghai Gynecologic Oncology Group | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| [Jiangsu Alphamab Biopharmaceuticals Co., Ltd](https://specstream.ai/data/clinical-trials/company/jiangsu-alphamab-biopharmaceuticals-co-ltd) | 1 |
| GOG Foundation | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |
| AGO Study Group | 1 |
| Genelux Corporation | 1 |
| M.D. Anderson Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 10 |
| China | 9 |
| South Korea | 6 |
| Taiwan | 6 |
| Germany | 5 |
| Canada | 5 |
| Italy | 5 |
| Israel | 4 |
| United Kingdom | 4 |
| Australia | 4 |
| Brazil | 4 |
| Japan | 4 |
| Spain | 4 |
| Austria | 3 |
| France | 3 |
| Greece | 3 |
| Mexico | 3 |
| Poland | 3 |
| Thailand | 3 |
| Switzerland | 2 |
| Argentina | 2 |
| Belgium | 2 |
| Chile | 2 |
| Colombia | 2 |
| Czechia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Metal suppliers in the United States](https://specstream.ai/data/businesses/metal-suppliers/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
- [Child psychiatry practices in the United States](https://specstream.ai/data/businesses/child-psychiatry-practices/united-states)
- [Woodworking supply stores in the United States](https://specstream.ai/data/businesses/woodworking-supply-stores/united-states)
- [Restaurant wholesale companies in the United States](https://specstream.ai/data/businesses/restaurant-wholesale-companies/united-states)
